CORDIS
EU research results

CORDIS

English EN
Integrated Training in Dry Eye Disease Drug Development (IT-DED3)

Integrated Training in Dry Eye Disease Drug Development (IT-DED3)

Objective

The European network for Integrated Training in Dry Eye Disease Drug Development (IT-DED3) aims to deliver multidisciplinary and entrepreneurial researchers trained to develop new therapies for patients suffering from dry eye diseases (DED). DED is a chronic, multifactorial disease of the ocular surface and is a major and increasing healthcare problem due to its high prevalence and economic burden because of the ageing population and frequent computer/tablet/smartphone usage.
New DED drug development and translation from “bench to bedside” is urgently needed and therefore IT-DED3 integrates world-class expertise in medicinal chemistry, process chemistry, ocular drug delivery and formulation, DED models, imaging, biomarker research and clinical ophthalmology. The scientific novelty is manifold, including new drug targets and compound classes, innovative formulation strategies for ocular drug delivery, and novel optical and molecular biomarkers identified by new imaging techniques and genomic-based systematic screening of a database of DED patients.
The consortium of 7 beneficiaries and 10 partners (in total 7 from the non-academic sector) from 8 different European countries will select 12 early stage researchers (ESRs). Each ESR will perform high level scientific research in this stimulating multidisciplinary, international and intersectoral environment. Besides the scientific skills, the Personal Career Development Plan (PCDP) of each ESR will include transferable skills such as data management, project and time management, communication and dissemination, IP and valorisation.
Both the research and training programme of IT-DED3 will deliver researchers with an enhanced career perspective and employability, who know how to use their entrepreneurial skills to move drug development projects in DED and other fields to the next technology readiness level.

Coordinator

UNIVERSITEIT ANTWERPEN

Address

Prinsstraat 13
2000 Antwerpen

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 751 680

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

SORBONNE UNIVERSITE

France

EU Contribution

€ 525 751,20

UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

France

UNIVERSIDAD DE VALLADOLID

Spain

EU Contribution

€ 495 745,92

LATVIJAS ORGANISKAS SINTEZES INSTITUTS

Latvia

EU Contribution

€ 223 577,64

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 269 145,36

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 498 432,96

INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA

Portugal

EU Contribution

€ 238 356,36

Partners (10)

Sort alphabetically

Expand all

Quintessence

MERCACHEM BV

HGBEYOND MATERIALS SICENCE SL

Riga Technical University

INSTITUTO DE TECNOLOGIA QUIMICA E BIOLOGICA - UNIVERSIDADE NOVA DE LISBOA

NOVALIQ GMBH

CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE DES QUINZE-VINGTS

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

HORUS PHARMA SAS

Heidelberg Engineering GmbH

Project information

Grant agreement ID: 765608

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2021

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 002 689,44

  • EU contribution

    € 3 002 689,44

Coordinated by:

UNIVERSITEIT ANTWERPEN

Belgium